Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–2 of 2 results
Advanced filters: Author: Peter Sjö Clear advanced filters

  • There is an urgent need for anti-virals targeting SARS-CoV-2. One of the most promising viral targets is the main protease of SARS-CoV-2, which is essential for viral replication and has no human analogue. Here, Abdelnabi et al. show that one of the most promising anti-virals (PF-07321332), currently in clinical trials, protects against SARS-CoV-2 alpha, beta and delta variant infection and provide evidence of reduced transmission.

    • Rana Abdelnabi
    • Caroline S. Foo
    • Johan Neyts
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-9

  • Patients with chronic inflammatory rheumatic diseases, such as primary Sjögren's syndrome, systemic lupus erhythematosus and rheumatoid arthritis, are at higher risk of developing B-cell non-Hodgkin lymphomas compared with the general population. In their Review, Dr Hansen, Dr Lipsky and Dr Dörner discuss the risk of lymphoma, the common and disease-specific mechanisms of B-cell lymphoma development, and the clinical consequences in patients with inflammatory rheumatic diseases.

    • Arne Hansen
    • Peter E Lipsky
    • Thomas Dörner
    Reviews
    Nature Clinical Practice Rheumatology
    Volume: 3, P: 561-569